DIRS.INFO The most relevant business & tech news

☆ Colonoscopies may not be as effective as thought, study suggests. Doctors disagree.
▼ + stars: | 2022-10-11 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Berkeley-Lovelace-Jr.Jpg | Berkeley Lovelace Jr. | ) www.nbcnews.com time to read: +7 min

What did the colonoscopy study find? With longer monitoring, the results could show a larger reduction of colon cancer risk, said Brawley of Johns Hopkins. Cancer experts reached Monday said their recommendation for colorectal cancer screening remains the same: Regular colonoscopies are key to preventing colon cancer and finding it early. In the U.S., “we have exaggerated the benefits of colon cancer screening,” Brawley said. “We have good studies that show that colon cancer screening is effective.

Amid concerns about Russian President Vladimir Putin’s recent nuclear threats came a bit of startling news: The U.S. Department of Health and Human Services said Tuesday that it spent $290 million on a drug to treat radiation sickness. Nplate, manufactured by U.S. drugmaker Amgen, was approved by the Food and Drug Administration in 2021 to treat injuries caused by acute radiation syndrome, also known as radiation sickness. Amgen will maintain the supply of the drug, an approach the HHS says lowers costs for taxpayers and allows the drug to be used in the commercial market before it expires. Chris Meekins, former deputy assistant secretary for preparedness and response at HHS, said that he sees no cause for alarm over the purchase. Greg Burel, the former director of the Strategic National Stockpile, agreed, saying that he doesn't think the HHS' purchase of the drug is related to the Russian invasion of Ukraine in February.

The Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness. The company said that in a phase 3 clinical trial, the drug, called lecanemab, slowed cognitive decline by 27% after 18 months. The results may offer renewed hope to Alzheimer’s patients after the U.S. drugmaker Biogen’s botched rollout of its drug, Aduhelm, last year. Biogen partnered with Eisai in the commercialization of the new drug, although Eisai led its development and the phase 3 trial. Two similar drugs — from Roche and Eli Lilly — are expected to release late-stage clinical trial results over the next few months.

☆ The Inflation Reduction Act aims to lower drug costs — but here’s how Big Pharma could get around it
▼ + stars: | 2022-09-20 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Berkeley-Lovelace-Jr.Jpg | Berkeley Lovelace Jr. | ) www.nbcnews.com time to read: +7 min

The Inflation Reduction Act is set to lower drug prices for millions of people in the United States — but experts fear pharmaceutical companies could exploit loopholes in the bill, ultimately keeping prescription costs high for many. The tactics may ultimately threaten the law’s ability to lower drug costs for consumers. Higher prices for new drugsOther experts are concerned about how companies might abuse the inflation rebate rule in the health law. The provision, which takes effect next year, imposes a rebate on drug manufacturers that raise the prices of their medications faster than inflation. By releasing new drugs at higher prices, drug companies will be able to make up for any lost revenue that they would normally receive from steadily raising prices each year, she said.

Patient advocates were disappointed with Sunday’s vote — Republican senators blocked the $35 insulin cap for private insurers — and expressed hope that federal and state measures could be included in legislation down the road. Clayton McCook of Edmond, Oklahoma, is among those who support capping the cost of insulin for people with private health insurance. A federal insulin cap for private insurance would have made “a huge difference to our family,” he said. “This year, with an evenly divided Senate, the insulin cap for people with private insurance didn’t secure enough votes,” Neuman said. McCook also advocated for changes besides a cap on insulin costs, saying Congress pass legislation that would lower the list price.

As yet another Alzheimer's drug targeting plaque buildup in the brain fails to improve cognition in patients, leading scientists said a significant shift is underway in the search for effective treatments for the disease. By 2050, that number is projected to rise to nearly 13 million, according to an estimate from the Alzheimer’s Association. Alzheimer’s disease is often referred to as “Type 3 diabetes,” a brain-specific form of diabetes that is the result of the brain’s neurons lacking glucose, said John Didsbury, the CEO of T3D Therapeutics. Data from the longest-ever phase 3 trial of exercise on cognition released at the conference on Tuesday found that exercise may stall cognitive decline in Alzheimer’s patients. He said it’s only a matter of time before we see more research discoveries that show potential for slowing Alzheimer’s disease, possibly within the next year or two.

The 26-year-old had been recently removed from his parents' health insurance plan and was about $300 short of the $1,300 he needed to pay for his insulin medication, his mother said. Though drugmakers often offer programs that can lower the out-of-pocket cost of insulin for both insured and uninsured patients, the financial burden can still be devastating for some. Why insulin remains unaffordableBut why does insulin — a medication that’s been around for more than 100 years — remain unaffordable for many people in the U.S.? Meanwhile, state and federal lawmakers are pushing for legislation that would lower the out-of-pocket cost for patients on insulin. She is pushing for more states to adopt the Alec Smith Insulin Affordability Act, which provides an emergency 30-day supply of insulin to patients for $35.

☆ WHO is investigating 1,716 health workers in China infected with coronavirus
▼ + stars: | 2020-02-14 | by ( Berkeley Lovelace Jr. | ) www.cnbc.com time to read: +4 min

World health officials are working with Chinese authorities to determine when the 1,716 health workers in the country were infected with the COVID-19 coronavirus, World Health Organization officials said Friday. Earlier in the day, China's National Health Commission said that 1,716 health workers in the country had been infected with the coronavirus and six of them have died. It was the first time China published figures specifically relating to infected medical personnel. She said there are currently no health workers in the U.S. that have contracted the virus. World health officials have said the respiratory disease is capable of spreading through human-to-human contact, droplets carried through sneezing and coughing and germs left on inanimate objects.

Search resuls for: "Berkeley Lovelace Jr"

8 mentions found